Management Team
Ceregene is proud of the management experience and talent we have implementing our mission to improve the quality of life for those affected by serious neurodegenerative disorders.
- Jeffrey M. Ostrove, Ph.D., President & Chief Executive Officer
- Raymond T. Bartus, Ph.D., Executive Vice President & Chief Scientific Officer
- Carolyn J. Bonebright, Controller
Prior to joining Ceregene as its first employee in April 2001, Dr. Ostrove was Chief Operating Officer of NeuroVir Therapeutics, Inc., located in Vancouver, B.C. and San Diego, California, and was instrumental in its merger with Medigene AG. Preceding NeuroVir (Medigene), Dr. Ostrove served as Senior Vice President and Chief Scientist of MAGENTA Corporation of Rockville, Maryland; a company he founded as a subsidiary of BioReliance, Inc., where he was also Vice President for Scientific Development. Dr. Ostrove also served on the staff of the National Institute of Allergy and Infectious Disease (NIAID) at the National Institutes of Health. He holds a Ph.D. in molecular biology from the University of Florida College of Medicine, and completed his post-doctoral training at The Johns Hopkins University School of Medicine.
Dr. Bartus joined Ceregene in December 2002, bringing over 30 years of experience in drug discovery, development and management from tenures at major multi-national pharmaceutical companies and smaller, development-stage biotech companies. He has general oversight and strategic responsibilities for Ceregene’s preclinical, clinical and regulatory activities. Prior to joining Ceregene, Dr. Bartus spent 10 years at Alkermes, as Senior Vice President for Preclinical Research and Development where he conceived and championed the preclinical development and initial clinical strategy for Alkermes’ only approved proprietary product, Vivitrol®. He is recognized as one of the originators of the ‘Cholinergic Hypothesis’, which led directly to the first four drugs approved by the FDA for Alzheimer’s disease. Dr. Bartus was the inaugural Editor-in-Chief for the scholarly journal Neurobiology of Aging and has served on several elite committees and panels, for the FDA, United States Congress and United States Secretary of Health and Human Services, among others. He has published extensively and is listed by the Institute of Scientific Information (ISI) as a “Highly Cited Researcher”, placing him in the top 0.5% of all scientists, based on the impact his research has had on neuroscience.
Ms. Bonebright joined Ceregene in October, 2004. She has over 20 years accounting and finance experience in the San Diego biotech and healthcare industries for start-up and established organizations. Ms. Bonebright earned her B.A. in Economics from San Diego State University.